Download Product Monograph

Table 1 Adverse Reactions
System Organ Class
Skin & subcutaneous tissue
disorders
Musculoskeletal, connective tissue
and bone disorders
Reproductive system and breast
disorders
General disorders and
administration site conditions
Investigations
Frequency Not Known
(Cannot be estimated from available data)
administration);
Increased appetite;
Nausea;
Elevation in serum liver enzyme levels (usually
reversible upon discontinuation)
Petechiae;
Ecchymosis;
Cutaneous and subcutaneous atrophy;
Skin atrophy;
Acne;
Dermatitis allergic;
Burning sensation or tingling (especially in the perineal
area, after intravenous injection);
Dry skin / Skin exfoliation;
Erythema;
Skin hyperpigmentation;
Skin hypopigmentation;
Hyperhidrosis;
Rash;
Abscess sterile;
Skin striae;
Alopecia
Myopathy;
Muscular weakness;
Osteonecrosis of femoral and humeral heads;
Osteoporosis;
Pathological fracture of long bones, postinjection flare
(following intra-articular use);
Growth retardation;
Neuropathic arthropathy;
Muscle atrophy;
Malaise
Menstruation irregular;
Spermatozoa progressive motility abnormal / sperm
concentration abnormal
Impaired healing;
Hiccups
Intraocular pressure increased;
Carbohydrate tolerance decreased;
Increased insulin requirement (or oral hypoglycemic
agents in diabetics);
Blood potassium decreased which are correctable and
15